Genesis Pharma

What Genesis Pharma does

Genesis Pharma is a privately-held biopharmaceutical commercialization company headquartered in Kifisiá (Chalandri), Athens, Greece, founded in 1997. The company operates as an exclusive regional commercial partner for leading global biotech and pharmaceutical innovators, commercializing their innovative therapies for chronic and rare diseases across Central and Eastern Europe and, since June 2026, the Nordic region. It does not develop proprietary molecules or own manufacturing; instead, it secures exclusive licensing and distribution rights and executes the full commercial stack, including market access, regulatory affairs, pricing and reimbursement, medical affairs, sales and marketing, distribution, and pharmacovigilance.

The portfolio comprises partner-sourced products spanning hematology, oncology, immunology, inflammatory diseases, neurology, rheumatology, and rare/orphan diseases, including RNAi therapeutics (Alnylam), gene therapy (Krystal Biotech), FLT3 inhibitors (Daiichi Sankyo), dissociative corticosteroids (Santhera), PD-1 inhibitors (Regeneron), kinase inhibitors (Deciphera, Incyte), and orphan biologics (Kyowa Kirin, Amicus). Distribution is executed through a network of wholly-owned subsidiaries in 11 jurisdictions plus a Cyprus-based intermediate holding company, with additional coverage in the Baltics, Western Balkans, and Malta operated from regional hubs. The company also maintains certified quality (ISO 9001), information security (ISO 27001), and anti-bribery (ISO 37001) management systems.

The business model is fee-and-margin-based commercialization under exclusive license and supply agreements with global pharma partners, with revenue generated through product sales, distribution margins, and commercialization services. Pricing is determined country-by-country through national regulatory and reimbursement processes and is not publicly disclosed. Customers in a B2B sense are the global pharma partners that license products to Genesis Pharma, while B2C demand is generated through healthcare professionals, hospitals, and specialty treatment centers across 17 European markets. The company employs approximately 200 people, the majority based in Greece, and reports no external institutional or private-equity ownership.

Name

Genesis Pharma

Legal name

GENESIS PHARMA S.A.

Website

https://genesispharma.com

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

101–250 employees

Short description

Genesis Pharma is a privately-held biopharmaceutical commercialization company that serves as the exclusive regional commercial partner for global biotech and pharma innovators, commercializing innovative therapies for chronic and rare diseases across 17 European markets.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Commercialization Services

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD)

akta.pro secondary industry

Biologics & Biosimilars Distributors (HLAIAJAH)

Keywords

• Biopharmaceutical commercialization
• Orphan drug distribution
• Specialty pharmaceutical licensing
• Rare disease therapies
• Pharmaceutical market access

Headquarters

HQ city

Kifisiá

HQ country

Greece

HQ region

Europe

Offices14 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Marketing or Sales, Operations, Infrastructure, Technology or R&D, Supply Chain

Revenue model

1. Product commercialization and distribution: GENESIS Pharma generates revenue by commercializing biopharmaceutical products under exclusive distribution and licensing agreements with global pharmaceutical and biotech companies. The company handles sales, marketing, medical affairs, regulatory affairs, pricing, and reimbursement across its geographic territory.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Genesis Pharma is a biopharmaceutical commercialization company that commercializes, promotes, distributes, and sells innovative medicines for chronic and rare diseases under exclusive licensing and supply agreements with global pharmaceutical and biotech partners. The company manages the full commercial lifecycle—sales, marketing, medical affairs, regulatory affairs, pricing, and reimbursement—across 17 European markets, serving as the regional commercial partner of choice for partners including Alnylam, Daiichi Sankyo, Otsuka, Krystal Biotech, Santhera, Regeneron, Deciphera, Incyte, Kyowa Kirin, and Amicus.

Product overview

GENESIS Pharma is a regional biopharmaceutical company that operates as a commercial partner for leading international biotech and pharmaceutical companies, specializing in the commercialization of innovative medicines for chronic and rare diseases in Central and Eastern Europe. The company does not develop its own drugs but instead secures exclusive rights to commercialize products from global partners including Alnylam (RNAi therapeutics), Daiichi Sankyo (quizartinib), Otsuka (donidalorsen), Krystal Biotech (beremagene geperpavec), Santhera (vamorolone), Regeneron (cemiplimab), Deciphera (ripretinib), Incyte (ponatinib, pemigatinib, tafasitamab), Kyowa Kirin (burosumab, mogamulizumab), and Amicus (migalastat). The portfolio covers therapeutic areas including hematology, oncology, immunology, inflammatory diseases, rare diseases, neurology, and rheumatology, with expertise in biopharmaceuticals and innovative orphan drugs.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Expanded partnership with Alnylam to cover 17 total markets including 4 Nordic countries
• +1 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

17 partnerships are on record, tiered core.

• Alnylam PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 10 June 2026GENESIS Pharma serves as the exclusive commercial partner for Alnylam's RNAi therapeutics portfolio across 17 markets in Europe (13 Southeast European markets plus 4 Nordic markets: Denmark, Finland, Norway, Sweden). The partnership, originally established in 2019, covers RNAi therapeutics for serious cardiomyopathy conditions and rare genetic diseases. Alnylam is a commercial-stage biopharmaceutical company with six approved medicines and reported 83% revenue growth.
• Daiichi SankyocoreChannel Partner/ Reseller/ Distributor · 7 January 2026Exclusive license and supply agreement for the distribution and commercialization of VANFLYTA (quizartinib) across 13 Central and Eastern European markets for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia. Daiichi Sankyo handles manufacturing and supply while GENESIS Pharma leads commercialization efforts in markets including Bulgaria, Croatia, Poland, Romania, and nine other countries.
• Otsuka Pharmaceutical Europe Ltd.coreChannel Partner/ Reseller/ Distributor · 15 December 2025Exclusive agreement for the commercialization of donidalorsen for hereditary angioedema in Central and Eastern Europe. The agreement covers 14 markets. The European Commission's review of the drug's authorization is ongoing as of December 2025.
• Krystal BiotechcoreChannel Partner/ Reseller/ Distributor · 10 November 2025Exclusive agreement for the distribution and commercialization of beremagene geperpavec-svdt (B-VEC), a topical gene therapy for dystrophic epidermolysis bullosa, across 12 Central and Eastern European markets including Greece, Cyprus, Romania, Bulgaria, Croatia, Malta, Serbia, North Macedonia, Bosnia & Herzegovina, Montenegro, Albania, and Kosovo.
• Santhera PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 11 September 2024Exclusive commercial agreement for vamorolone for Duchenne Muscular Dystrophy treatment across 20 markets in Central and Eastern Europe, including Greece, Cyprus, Malta, Romania, Bulgaria, Slovenia, Croatia, Poland, Czech Republic, Hungary, Slovakia, Lithuania, Latvia, Estonia, Serbia, North Macedonia, Bosnia-Herzegovina, Montenegro, Albania, and Kosovo.
• Regeneron Pharmaceuticals (via Regeneron Ireland DAC)coreChannel Partner/ Reseller/ Distributor · 1 March 2024Exclusive distribution agreement for cemiplimab (PD-1 inhibitor) in Greece, Cyprus, and Malta for the treatment of advanced basal cell carcinoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, and cervical cancer.
• Deciphera PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 9 January 2024Exclusive distribution agreement for ripretinib (QINLOCK) for fourth-line treatment of gastrointestinal stromal tumor (GIST) across 14 Central and Eastern European markets including Greece, Cyprus, Bulgaria, Estonia, Croatia, Latvia, Lithuania, Malta, Hungary, Poland, Romania, Slovakia, Slovenia, and Czech Republic.
• Kyowa KirincoreChannel Partner/ Reseller/ Distributor · 20 December 2022Commercial partnership for orphan drug portfolio in Greece, Cyprus, and Malta. GENESIS Pharma commercializes burosumab for X-linked hypophosphatemia and tumor-induced osteomalacia, and mogamulizumab for cutaneous T-cell lymphoma subtypes.
• Incyte Biosciences International SàrlcoreChannel Partner/ Reseller/ Distributor · 25 October 2022Expansion of exclusive supply and distribution agreement covering ponatinib plus two new oncology drugs (pemigatinib and tafasitamab) across 11 markets including Greece, Cyprus, Croatia, Slovenia, Malta, Serbia, North Macedonia, Bosnia-Herzegovina, Kosovo, Albania, and Montenegro. Original six-year collaboration began in 2016.
• SeagencoreChannel Partner/ Reseller/ Distributor · 20 October 2021Exclusive collaboration for an innovative oncology therapy for HER2-positive, locally advanced or metastatic breast cancer in Greece, Cyprus, and Malta.
• Jazz PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 29 September 2021Exclusive collaboration for an oncology treatment for high-risk acute myeloid leukemia (t-AML and AML-MRC) in Greece, Cyprus, and Malta.
• Amicus TherapeuticscoreChannel Partner/ Reseller/ Distributor · 12 March 2019Exclusive rights to commercialize migalastat in Greece, Cyprus, Romania, and Bulgaria for the treatment of Fabry disease. GENESIS Pharma is responsible for sales, marketing, medical affairs, regulatory, and reimbursement support. The European Commission granted full approval for migalastat in May 2016.
• BiogencoreChannel Partner/ Reseller/ DistributorListed as a partner on the company website. Biogen is a leading global biopharmaceutical company with products in neurology, immunology, and rare diseases.
• CSL ViforcoreChannel Partner/ Reseller/ DistributorListed as a partner on the company website. CSL Vifor specializes in rare diseases, transplant, and cardio-renal therapies.
• Pharma MarcoreChannel Partner/ Reseller/ DistributorListed as a partner on the company website. Pharma Mar is a Spanish biopharmaceutical company focused on oncology.
• Regeneron (additional reference)coreChannel Partner/ Reseller/ DistributorListed as a partner on the company website (in addition to the formalized Seagen partnership).
• Krystal BiocoreChannel Partner/ Reseller/ DistributorListed as a partner on the company website (partner for gene therapy beremagene geperpavec).

Scale indicators5 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Swixx BioPharma: Switzerland-based biopharma commercialization company that partners with global pharma and biotech to launch and commercialize products across CEE, CIS, and MEA — directly comparable business model to GENESIS.
• Ewopharma: Swiss-headquartered specialty biopharma commercialization partner focused on Central and Eastern Europe, operating a similar regional exclusive-distribution and market-access model with global pharma partners.

Emerging players

• NewBridge Pharmaceuticals: Dubai-based regional biopharma commercialization partner focused on the Middle East and Africa, operating the same 'exclusive partner for global pharma in emerging markets' model as GENESIS but in a different geography.
• Biopas Laboratories: LATAM-focused biopharma commercialization and distribution partner representing global pharma companies, structurally similar to GENESIS in providing regional market access for international specialty drug portfolios.

Broad incumbents

• Gedeon Richter: Hungary-headquartered major pharmaceutical company with deep CEE presence and a specialty/biologics portfolio — broader and vertically integrated but operates in the same CEE geographies and therapeutic areas as GENESIS.
• KRKA: Slovenia-based pharmaceutical manufacturer with strong CEE and Eastern European commercial reach — competes for the same regional distribution relationships and pharmacy/payer relationships as GENESIS.
• Egis Pharmaceuticals: Hungary-based pharmaceutical group with broad CEE distribution and specialty pharma presence — comparable CEE footprint and channel relationships, though with proprietary products rather than the pure distribution model.
• Zentiva: Czech Republic-based European generics and specialty pharma company with significant CEE presence — comparable regional channel and market-access footprint.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/genesis-pharma

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genesis Pharma